Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Life and Medical Sciences  (2)
  • prostate  (1)
  • 1
    ISSN: 1573-0646
    Schlagwort(e): prostate ; topotecan ; topoisomerase I
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Chemie und Pharmazie , Medizin
    Notizen: Summary Systemic chemotherapy with currently available agents has not improved survival for patients with hormone refractory prostate cancer (HRPC), consequently, the evaluation of new agents is warranted. Topotecan is a specific inhibitor of topoisomerase I with broad antitumor activity in preclinical studies. The purpose of this phase II trial was to determine the objective response rate of topotecan administered as a 30 minute infusion for five consecutive days in men with metastatic HRPC. Thirty-four evaluable patients were treated with topotecan 1.1–1.5 mg/m2 as a 30 minute infusion daily for five days, repeated every three weeks until disease progression or unacceptable toxicity. Response was assessed with a combination of standard solid tumor response criteria and the serum prostate specific antigen (PSA) for patients with bidimensionally measurable disease, and by serial measurements of the PSA in patients with bone only (evaluable) disease. One of 13 patients (7.6%) with measurable soft tissue disease had a PR in nodal sites. Of 21 patients with only osseous metastases, 1 (4.7%) had improvement in bone scan. Six of the 34 evaluable patients (17.6%) had the serum PSA decrease by ≥ 50% and 2 (5.8%) had PSA decreases of ≥ 75%. Toxicity was chiefly hematologic with 66% of patients experiencing Grade 3 or 4 granulocytopenia. Thirty-nine percent of cycles required a delay to allow for hematologic recovery and ten patients required red cell transfusions. Nonhematologic toxicity, mainly nausea and alopecia, was mild. Topotecan administered at this dose and schedule has limited activity in patients with HRPC. Further trials of topo I inibition in HRPC should utilize alternative schedules of topotecan (e.g.), prolonged infusion) or other camptothecin analogs with more potent topo I inhibitory activity.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Digitale Medien
    Digitale Medien
    New York, NY [u.a.] : Wiley-Blackwell
    The @Anatomical Record 218 (1987), S. 73-87 
    ISSN: 0003-276X
    Schlagwort(e): Life and Medical Sciences ; Cell & Developmental Biology
    Quelle: Wiley InterScience Backfile Collection 1832-2000
    Thema: Medizin
    Notizen: The present study documents the morphological changes in the aging human olfactory bulb. Eight bulb pairs from white females between the ages of 25 and 102 years were used. The number of mitral cells in layers IV and III was determined for each bulb and corrected for spilt cell error. Counts were made on 10-μm thick Nissl-stained sections at 250-μm intervals. The mean number of mitral cells per olfactory bulb at age 25 was estimated from linear regression to be 50,935; at age 60, 32,718; and at age 95, 14,501. The average loss over the time interval studied was 520 mitral cells per year.The volume of each bulb layer, except layer IV, was determined. The difference in the volume of each layer within individuals with age and the total volume with age was not significant (P 〈 0.11). The estimated mean bulb volume was found to be 50.02, 43.35, and 36.68 mm3 at ages 25, 60, and 95 years, respectively. The estimated reduction in bulb volume per year increase of age was 0.19 mm3. The ratio of mitral cells to bulb volume for layer III decreased by 19.4 units for every year increase in age. No significant difference was found between the left and the right bulbs in regard to the number of mitral cells and the bulb volume.Histologically, the glomerular layer thickness as well as the mitral cell size and concentration per unit area decreased with age. The intrabulbar anterior olfactory nucleus was discontinuous, highly variable in size, and presumably variable even in neuronal numbers.
    Zusätzliches Material: 12 Ill.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Digitale Medien
    Digitale Medien
    Hoboken, NJ [u.a.] : Wiley-Blackwell
    Journal of Orthopaedic Research 4 (1986), S. 494-498 
    ISSN: 0736-0266
    Schlagwort(e): Local administration ; Antibiotics ; Stability ; Pump ; Osteomyelitis ; Life and Medical Sciences
    Quelle: Wiley InterScience Backfile Collection 1832-2000
    Thema: Medizin
    Notizen: We measured the stability of vancomycin, amikacin, netilmicin, tobramycin, gentamicin, clindamycin, and aztreonam in an implantable drug pump. Two pumps were filled with the antibiotic being tested and were incubated at 37° for 3 weeks. Samples were taken daily. At 3 weeks the pumps were disassembled and examined microscopically for signs of deterioration. If the pumps were intact, bioassays were used to quantitate the biologic activity of each daily antibiotic sample. Vancomycin degraded the pump. Amikacin, netilmicin, tobramycin, gentamicin, clindamycin, and aztreonam had no effect on the pump and maintained their biologic activity over the 3-week period.
    Zusätzliches Material: 6 Ill.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...